Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target

Malarial dihydrofolate reductase (DHFR) is the target of antifolate antimalarial drugs such as pyrimethamine and cycloguanil, the clinical efficacy of which have been compromised by resistance arising through mutations at various sites on the enzyme. Here, we describe the use of cocrystal structures...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Yuthavong, Yongyuth, Tarnchompoo, Bongkoch, Vilaivan, Tirayut, Chitnumsub, Penchit, Kamchonwongpaisan, Sumalee, Charman, Susan A., McLennan, Danielle N., White, Karen L., Vivas, Livia, Bongard, Emily, Thongphanchang, Chawanee, Taweechai, Supannee, Vanichtanankul, Jarunee, Rattanajak, Roonglawan, Arwon, Uthai, Fantauzzi, Pascal, Yuvaniyama, Jirundon, Charman, William N., Matthews, David
Format: Artigo
Sprache:Inglês
Veröffentlicht: National Academy of Sciences 2012
Schlagworte:
Biological Sciences
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3479511/
https://ncbi.nlm.nih.gov/pubmed/23035243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1204556109
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge